In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Esperion sold by Pfizer; closes $55.8mm Series A round

03 May 2013

Executive Summary

After acquiring Esperion Therapeutics (cardiovascular and metabolic compounds) in 2003 for $1.25bn, Pfizer has now decided to spin off the company to a syndicate of investors. Esperion has simultaneously closed a tranched $22.75mm Series A venture round co-led by new investors Aisling Capital and Domain Associates, and returning backer Alta Partners, all of which contribute one member to the company's board. Arboretum Ventures also participated.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Spin-Off
    • Venture Financing

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By